Auto Refresh

Coronavirus LIVE Updates: Centre's 'Warm Regards' to States over Alarmingly Low Testing Amid Wedding, Festive Season

Coronavirus LIVE Updates: India added 9,283 new coronavirus infections taking the country's total tally of COVID-19 cases to 3,45,35,763 while the active cases declined to 1,11,481, the lowest in 537 days

News18.com | November 24, 2021, 18:01 IST
Covid-19

Coronavirus Live Updates: India added 9,283 new coronavirus infections taking the country’s total tally of COVID-19 cases to 3,45,35,763 while the active cases declined to 1,11,481, the lowest in 537 days, according to the Union Health Ministry data updated on Wednesday. The death toll climbed to 4,66,584 with 437 fresh fatalities, according to the data updated at 8 am. Read More

Nov 24, 2021 18:01 IST

9 More Army Officers in Indore Test Positive for Coronavirus

Nine more fully-vaccinated Army officers, participating in a course at the Indian Institute of Management (IIM) in Madhya Pradesh’s Indore, tested positive for coronavirus, taking the number of the infected officers pursuing this course to 11 in the last four days, a health official said on Wednesday. These Army officers are pursuing a six-month certificate course in Business Management for Defence Officers (CCBMDO) at IIM.

Nov 24, 2021 16:57 IST

With 11% Rise, Europe is Only Region with More Covid Cases

The World Health Organization said that coronavirus cases jumped by 11% in Europe in the last week, the only region in the world where COVID-19 has continued to increase since mid-October. In its weekly assessment of the pandemic released on Tuesday, the U.N. health agency said cases and deaths globally have risen by about 6%, with about 3.6 million new infections and 51,00 new deaths reported in the previous week.

Nov 24, 2021 13:47 IST

Exposure to Harmless Coronaviruses Boosts Immunity Against COVID-19: Study

People who have had strong immune response to other human coronaviruses may also have some protection against the SARSCoV2 virus that causes COVID19, according to a study. The research, published in the journal Nature Communications, used a specially developed test to analyse antibody levels against four other human coronaviruses in 825 blood samples taken before SARSCoV2 emerged.

Nov 24, 2021 13:47 IST

Germany Faces Grim COVID Milestone with Leadership in Flux

Germany is set to mark 100,000 deaths from COVID-19 this week, passing a somber milestone that several of its neighbors crossed months ago but which Western Europe’s most populous nation had hoped to avoid. Teutonic discipline, a robust health care system and the rollout of multiple vaccines one of them homegrown were meant to stave off a winter surge of the kind that hit Germany last year. Yet complacency and a national election, followed by a drawn-out government transition, saw senior politicians dangle the prospect of further lifting restrictions even as Germanys infection rate rose steadily this fall.

Nov 24, 2021 12:49 IST

Delta Variant Can Infect Fully Vaccinated Individuals: Study

A study has revealed that the highly transmissible Covid Delta variant can infect individuals who have been fully vaccinated against the virus. The study was conducted by the Indian SARS-CoV-2 Genomics Consortium (INSACOG), Council Of Scientific And Industrial Research (CSIR) and the National Centre for Disease Control in two Delhi hospitals.

Nov 24, 2021 12:43 IST

Covaxin Only 50% Effective Against Symptomatic Covid-19 in Real-world Assessment. What It Means for You

ALancet study based on the first real-world assessment shows two doses of Covaxin are 50 per cent effective against symptomatic Covid-19, opening up a host of questions about India’s indigenous coronavirus vaccine, which has been driving the vaccination coverage in the country. The results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns. The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15-May 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection. Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed Covid-19 cases. Read the full story here.

Nov 24, 2021 12:42 IST

Fall in COVID-19 Testing Worries Authorities

An alarming fall in testing for COVID-19 threatens to undermine India’s efforts to contain the pandemic, the Union health ministry said on Wednesday in a letter to state governments, as worries grew over fresh waves of infection abroad. “In the absence of sustained levels of sufficient testing, it is very difficult to determine the true level of infection spread in a geography,” Health Secretary Rajesh Bhushan said in a letter sent to the northeastern state of Nagaland, which has reduced testing by more than a third in two months.

Nov 24, 2021 11:34 IST

Centre Writes to States to Act with Caution Amid Festive, Wedding Season

Nov 24, 2021 10:29 IST

Exposure to Harmless Coronaviruses Boosts COVID Immunity: Study

Immune responses to other human coronaviruses, which mostly only cause harmless colds, can provide some protection against SARSCoV2 (COVID19), according to new research published in the journal Nature Communications’. It is known that infections with the novel coronavirus, which causes COVID19, and vaccination lead to strong antibody responses against SARSCoV2.

This week, researchers at the University of Zurich (UZH) revealed a cross-reactive immune response which experts believe could be an important piece of the puzzle of how to achieve comprehensive coronavirus immunity. People who have had strong immune responses to other human coronaviruses also have some protection against SARS-CoV-2 infection, said Alexandra Trkola, head of the Institute of Medical Virology at UZH.

Nov 24, 2021 10:23 IST

Scientists Find Coronaviruses Closely Related to Pandemic Virus

A team of scientists has identified coronaviruses closely related to SARS-CoV-2 from two bats sampled in Cambodia more than a decade ago. The discovery described in the journal Nature Communications, along with the recent detection of the closest ancestors of SARS-CoV-2 known to date in cave-dwelling bats in Laos, indicates that SARS-CoV-2-related viruses that cause COVID-19 have a much wider geographic distribution than previously reported and further supports the hypothesis that the pandemic originated via spillover of a bat-borne virus.

Nov 24, 2021 10:21 IST

US to Require Vaccines for All Border Crossers in January

President Joe Biden will require essential, nonresident travelers crossing U.S. land borders, such as truck drivers, government and emergency response officials, to be fully vaccinated beginning on Jan. 22, the administration planned to announce Tuesday. A senior administration official said the requirement, which the White House previewed in October, brings the rules for essential travelers in line with those that took effect earlier this month for leisure travelers, when the U.S. reopened its borders to fully vaccinated individuals.

Nov 24, 2021 10:21 IST

Laos Becomes the 20th Country to Authorize the One-shot Sputnik Light Vaccine

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) today announced the Russian single-component Sputnik Light vaccine against coronavirus has been approved in Lao People’s Democratic Republic. Thus Laos has become the 20th country to register Sputnik Light. Sputnik Light vaccine is based on human adenovirus serotype 26, which is the first component of the Sputnik V vaccine. In March 2021 the two-dose Sputnik V was also authorized in Laos. Both Sputnik Light and Sputnik V vaccines have been approved under the emergency use authorization procedure.

Nov 24, 2021 10:20 IST

Active COVID-19 Cases in Country Lowest in 537 Days

India added 9,283 new coronavirus infections taking the country’s total tally of COVID-19 cases to 3,45,35,763 while the active cases declined to 1,11,481, the lowest in 537 days, according to the Union Health Ministry data updated on Wednesday. The death toll climbed to 4,66,584 with 437 fresh fatalities, according to the data updated at 8 am.

The daily rise in new coronavirus infections has been below 20,000 for 47 straight days and less than 50,000 daily new cases have been reported for 150 consecutive days now. The active cases comprise 0.32 per cent of the total infections, the lowest since March 2020, while the national COVID-19 recovery rate was recorded at 98.33 per cent, the highest since March 2020, the ministry said.

Nov 24, 2021 09:39 IST

Over 9k New Covid Cases in India

India reports 9,283 new cases, 10,949 recoveries & 437 deaths in the last 24 hours, as per Health Ministry. Active cases stand at 1,11,481 – lowest in 537 days

Nov 24, 2021 09:28 IST

Covid Deaths in Europe Could Reach 2.2mn by Spring 2022: WHO

The World Health Organization’s (WHO) Regional Office for Europe said on Wednesday that the cumulative reported Covid-19 deaths across the continent are projected to reach over 2.2 million by spring next year, based on current trends. The projection comes as the region remains in the grip of the pandemic, with the number of reported deaths increasing to close to 4,200 per day, up from 2,100 per day at the end of September, Xinhua news agency.

Nov 24, 2021 09:04 IST

Thane's COVID-19 Case Count Grows by 68, Death Toll by Two

Thane district of Maharashtra reported 68 new coronavirus positive cases, taking its infection tally to 5,68,615, while the death of two patients pushed the toll to 11,576, an official said on Wednesday. These cases and fatalities were reported on Tuesday. Thane’s COVID19 mortality rate is 2.03 per cent, he added.

Nov 24, 2021 08:21 IST

AstraZeneca Chief Credits Oxford Vaccine with UK's COVID Fight

The Chief Executive of AngloSwedish biopharma major AstraZeneca, which helped produce the Oxford University’s vaccine to protect against COVID19, on Tuesday credited it for the UK’s relatively better hospitalisation rates amid the pandemic wave hitting Europe. Pascal Soirot said the Oxford/AstraZeneca vaccine, being developed and administered in India as Covishield, was initially not used by the European Union (EU) for older age groups due to some doubts cast around efficacy. While in Britain the vaccine was widely used in the early stages for the most vulnerable and older age groups, the EU had chosen other vaccines instead. Its medical regulator approved the use of the Oxford/AstraZeneca vaccine for all age groups only in January.

Nov 24, 2021 08:21 IST

AstraZeneca Chief Credits Oxford Vaccine with UK's COVID Fight

The Chief Executive of AngloSwedish biopharma major AstraZeneca, which helped produce the Oxford University’s vaccine to protect against COVID19, on Tuesday credited it for the UK’s relatively better hospitalisation rates amid the pandemic wave hitting Europe. Pascal Soirot said the Oxford/AstraZeneca vaccine, being developed and administered in India as Covishield, was initially not used by the European Union (EU) for older age groups due to some doubts cast around efficacy. While in Britain the vaccine was widely used in the early stages for the most vulnerable and older age groups, the EU had chosen other vaccines instead. Its medical regulator approved the use of the Oxford/AstraZeneca vaccine for all age groups only in January.

Nov 24, 2021 07:49 IST

Most Covid-19 Facilities in Bengal to Turn into Non-Covid Units as Infections Ebb

The West Bengal Health Department has decided to turn most hospitals, which were made dedicated COVID-19 facilities, into non-Covid-units, after a decline in the number of fresh cases, a senior official said on Tuesday. It has also decided to shut several safe homes that were set up during the peak phase of the pandemic to accommodate infected patients, he said. Read the full story here.

Nov 24, 2021 07:47 IST

India 'Deeply Examining' Data on Booster Shots, Will Approve Once Science Agrees: Covid Task Force Head

India will start administering coronavirus vaccine booster doses once all scientific aspects are “deeply examined”, chief of the country’s Covid task force Dr VK Paul said on Tuesday. “While several studies are coming out, we still are looking for accurate answers to understand which one is the right booster and what is the correct interval to start jabbing,” said Dr Paul, while adding that “once science says it should be given, it will be given”. Read the full story here.

Maharashtra Health Minister Rajesh Tope on Wednesday said that there is a third wave of Covid-19 infections waiting due to which the state has also recommended vaccination for children in the 12 to 18 age bracket. The state is likely to reopen schools from primary onwards within a fortnight, Tope said.

Tope told CNN-News18, “The health department had given a go-ahead for reopening of all schools. The department has also recommended vaccination of 12 to 18 age group of children. Experts have predicted the cycle of the Covid-19 virus, and the third wave is expected in December accordingly. But it will be mild if the Vaccination process is on track.”

On the contrary, AIIMS Director Dr Randeep Guleria on Tuesday evening ruled out the possibility of a “huge third wave” as the infection rate and severity is “declining each passing day”. “The vaccines are holding up, we are not seeing breakthrough infections causing a surge in our admissions, our sero-positivity rate is very high. All of these suggest that as of now, we really don’t need a booster dose. We may need it in the future, that is definitely there. But as of now we don’t need a booster dose,” he said at the launch of “Going Viral”, a book on the making of Bharat Biotech’s Covaxin.

“We are well protected and I think we should focus on getting more and more people to get the first and second dose because if we have that number in a sufficiently large amount, we will be well protected as a country,” he said.

Meanwhile, Pfizer and BioNTech said Monday their COVID-19 vaccine remained 100 per cent effective in children 12 to 15 years old, four months after the second dose.

The companies said that the new data, which involved 2,228 trial participants, will help support their applications for full approval in the United States and worldwide.

No serious safety concerns were observed in individuals with at least six months of follow-up after the second dose.

Read all the Latest News, Breaking News and Coronavirus News here. Follow us on Facebook, Twitter and Telegram.